Incyte Corporation Dividend History (INCY)

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company founded in 1991 and headquartered in Wilmington, Delaware. It is primarily focused on the discovery, development, and commercialization of proprietary therapeutics to meet unmet medical needs, especially in oncology and hematology. The company has developed noteworthy products such as Jakafi (ruxolitinib), a treatment for myelofibrosis and polycythemia vera, which has significantly contributed to its growth and reputation in the biotech industry. As of 2023, Hervé Hoppenot serves as the CEO of Incyte. Incyte’s commitment to innovation is reflected in its robust pipeline of drugs in various stages of clinical trials. The company has seen substantial financial growth over the years, with revenues reaching several billion dollars, underscoring its impact in the pharmaceutical sector.